ATE530184T1 - Piperazinon-verbindungen als tumor- und krebsbekämpfende wirkstoffe - Google Patents
Piperazinon-verbindungen als tumor- und krebsbekämpfende wirkstoffeInfo
- Publication number
- ATE530184T1 ATE530184T1 AT08105065T AT08105065T ATE530184T1 AT E530184 T1 ATE530184 T1 AT E530184T1 AT 08105065 T AT08105065 T AT 08105065T AT 08105065 T AT08105065 T AT 08105065T AT E530184 T1 ATE530184 T1 AT E530184T1
- Authority
- AT
- Austria
- Prior art keywords
- tumor
- active ingredients
- cancer active
- compounds
- piperazinone
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical class O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 title 1
- 230000001093 anti-cancer Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31479501P | 2001-08-24 | 2001-08-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE530184T1 true ATE530184T1 (de) | 2011-11-15 |
Family
ID=23221472
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02796419T ATE447955T1 (de) | 2001-08-24 | 2002-08-23 | Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel |
| AT08105065T ATE530184T1 (de) | 2001-08-24 | 2002-08-23 | Piperazinon-verbindungen als tumor- und krebsbekämpfende wirkstoffe |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02796419T ATE447955T1 (de) | 2001-08-24 | 2002-08-23 | Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7763620B2 (de) |
| EP (2) | EP2014291B1 (de) |
| JP (1) | JP2005504771A (de) |
| AT (2) | ATE447955T1 (de) |
| AU (1) | AU2002332640B2 (de) |
| CA (1) | CA2458009C (de) |
| DE (1) | DE60234354D1 (de) |
| ES (2) | ES2376399T3 (de) |
| WO (1) | WO2003017939A2 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2041088B1 (de) | 2006-06-28 | 2014-01-08 | Amgen Inc. | Inhibitoren des glycintransporters 1 |
| US20100311749A1 (en) | 2007-10-26 | 2010-12-09 | Laura Jane Chambers | 4-benzoyl-1-substituted-piperazin-2-one derivatives as p2x7 modulators |
| KR100967171B1 (ko) * | 2007-12-26 | 2010-07-05 | 재단법인서울대학교산학협력재단 | Δ5-2-옥소피페라진 유도체 및 그의 고체상 합성 방법 |
| PL2303846T3 (pl) * | 2008-06-24 | 2015-10-30 | Sanofi Sa | Podstawione izochinoliny i izochinolinony jako inhibitory kinazy Rho |
| WO2010088457A2 (en) * | 2009-01-29 | 2010-08-05 | H. Lee Moffitt Cancer And Research Institute, Inc. | Methods for inducing tumor regression, inhibiting tumor growth, and inducing apoptosis in breast tumors with geranylgeranyltransferase i inhibitors |
| WO2010149943A1 (en) * | 2009-06-25 | 2010-12-29 | Oncorel Ab | New compounds and medical use |
| KR101162100B1 (ko) | 2010-01-19 | 2012-07-02 | 한미사이언스 주식회사 | 세포사멸 유도 활성을 갖는 신규 피라지논 유도체 및 이를 활성성분으로 포함하는 약학 조성물 |
| ES2572604T3 (es) * | 2011-10-03 | 2016-06-01 | Euroscreen S.A. | Nuevas N-acil-5,6,7,(8-sustituido)-tetrahidro-[1,2,4]triazolo[4,3a]pirazinas quirales, como antagonistas selectivas del receptor de NK-3, composición farmacéutica y métodos para uso en trastornos mediados por el receptor de NK-3 |
| KR20200066690A (ko) | 2017-10-16 | 2020-06-10 | 칭화대학교 | 메발로네이트 경로 억제제 및 이의 약제학적 조성물 |
| US10710975B2 (en) | 2017-12-15 | 2020-07-14 | Inthera Bioscience AG | Oxopiperazine derivatives |
| AR116020A1 (es) | 2018-09-03 | 2021-03-25 | Bayer Ag | COMPUESTOS DE 3,9-DIAZAESPIRO[5.5]UNDECANO COMO INHIBIDORES DE GGTasa I Y SU USO PARA EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS |
| WO2020048827A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
| WO2020048830A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds |
| WO2020048826A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds |
| WO2020048831A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds |
| WO2020048828A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL47168A (en) * | 1974-05-09 | 1979-07-25 | Toyama Chemical Co Ltd | Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same |
| US4251438A (en) | 1979-06-14 | 1981-02-17 | The Upjohn Company | Piperazinone and piperazine polypeptides |
| US5284828A (en) | 1990-05-14 | 1994-02-08 | Fujisawa Pharmaceutical Co. Ltd. | Peptide compound and its preparation |
| CZ189197A3 (cs) | 1994-12-23 | 1998-01-14 | Dr. Karl Thomae Gmbh | Piperazinové deriváty, způsob výroby a farmaceutický prostředek s jejich obsahem |
| US5885995A (en) * | 1996-04-03 | 1999-03-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| BR9713744A (pt) * | 1996-12-17 | 2000-03-21 | Warner Lambert Co | Inibidores de cicloalquia da proteìna farnesil transferase |
| CA2301770A1 (en) | 1997-08-27 | 1999-03-04 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| ZA99607B (en) | 1998-01-27 | 1999-07-27 | Rhone Poulenc Rorer Pharma | Substituted oxoazaheterocyclyl factor xa inhibitors. |
| JP2003529531A (ja) | 1998-11-25 | 2003-10-07 | アヴェンティス ファーマシューティカルズ インコーポレイテッド | 置換オキソアザへテロシクリルＸａ因子阻害剤 |
| EP1165082A4 (de) | 1999-03-03 | 2002-06-12 | Merck & Co Inc | Inhibitoren der prenyl-protein-transferase |
| DE60041584D1 (de) * | 1999-07-28 | 2009-04-02 | Aventis Pharma Inc | Substituierte oxoazaheterozyclische verbindungen |
-
2002
- 2002-08-23 CA CA2458009A patent/CA2458009C/en not_active Expired - Lifetime
- 2002-08-23 AT AT02796419T patent/ATE447955T1/de not_active IP Right Cessation
- 2002-08-23 ES ES08105065T patent/ES2376399T3/es not_active Expired - Lifetime
- 2002-08-23 JP JP2003522462A patent/JP2005504771A/ja active Pending
- 2002-08-23 AU AU2002332640A patent/AU2002332640B2/en not_active Expired
- 2002-08-23 ES ES02796419T patent/ES2335092T3/es not_active Expired - Lifetime
- 2002-08-23 EP EP08105065A patent/EP2014291B1/de not_active Expired - Lifetime
- 2002-08-23 US US10/484,560 patent/US7763620B2/en active Active
- 2002-08-23 WO PCT/US2002/026881 patent/WO2003017939A2/en active Application Filing
- 2002-08-23 DE DE60234354T patent/DE60234354D1/de not_active Expired - Lifetime
- 2002-08-23 AT AT08105065T patent/ATE530184T1/de not_active IP Right Cessation
- 2002-08-23 EP EP02796419A patent/EP1427418B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002332640B2 (en) | 2007-11-08 |
| DE60234354D1 (de) | 2009-12-24 |
| CA2458009C (en) | 2011-08-16 |
| US20080221123A1 (en) | 2008-09-11 |
| WO2003017939A2 (en) | 2003-03-06 |
| ES2376399T3 (es) | 2012-03-13 |
| EP2014291A3 (de) | 2009-06-17 |
| EP2014291A2 (de) | 2009-01-14 |
| EP2014291B1 (de) | 2011-10-26 |
| US7763620B2 (en) | 2010-07-27 |
| EP1427418A2 (de) | 2004-06-16 |
| ATE447955T1 (de) | 2009-11-15 |
| CA2458009A1 (en) | 2003-03-06 |
| EP1427418B1 (de) | 2009-11-11 |
| JP2005504771A (ja) | 2005-02-17 |
| EP1427418A4 (de) | 2004-11-17 |
| WO2003017939A3 (en) | 2003-11-13 |
| ES2335092T3 (es) | 2010-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120977T1 (el) | Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι | |
| ATE530184T1 (de) | Piperazinon-verbindungen als tumor- und krebsbekämpfende wirkstoffe | |
| IS2114B (is) | Kínasólínafleiður til að meðhöndla æxli | |
| DE69931766D1 (de) | Antitumorale mittel | |
| ATE506953T1 (de) | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel | |
| MY129809A (en) | Quinazoline derivatives | |
| ATE407928T1 (de) | Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung | |
| IL176007A0 (en) | Antibodies specific to c35 and pharmaceutical compositions containing the same | |
| WO2003075850A3 (en) | Methods for alzheimer's disease treatment and cognitive enhancement | |
| CY1110914T1 (el) | Δικυκλο-πυραζολες δραστικες ως αναστολεις kinασων, διεργασια για την παρασκευη τους και φαρμακευτικες συνθεσεις που τις περιλαμβανουν | |
| NO20014415D0 (no) | Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens | |
| YU54202A (sh) | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije | |
| BRPI0207961A8 (pt) | Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
| BRPI0415525A (pt) | derivados de imidazola e seu uso como agentes farmacêuticos | |
| EA200200616A1 (ru) | Химические производные и их применение в качестве антителомеразного агента | |
| DE60033649D1 (de) | Verbindungen und therapeutische methoden | |
| DE60229046D1 (de) | Chinazolin derivate | |
| BR0201862A (pt) | Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos | |
| DE60301339D1 (de) | Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen | |
| DE60137146D1 (de) | Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten | |
| MXPA06007007A (es) | Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores. | |
| HK1074840A1 (en) | Novel dithiolopyrrolones with therapeutic activity | |
| BR0008307A (pt) | Utilização de uma proteìna ompa de enterobactéria ou de um de seus fragmentos, e, composição farmacêutica | |
| DE69814691D1 (de) | Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten | |
| DE59101818D1 (de) | Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |